Anti-Interleukin-5 in the Management of Eosinophilic Asthma: A Review of Effectiveness, Safety, and Budgetary Impact From the Perspective of the Brazilian Health System
| Autor: | Ruberlei Godinho de Oliveira, Luisa Daige Marques, Kelli Carneiro de Freitas Nakata, Helder Cássio de Oliveira, Clóvis Botelho, Graciane Catarina Batista Magalhães |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Budgets
medicine.medical_specialty Exacerbation Economics Econometrics and Finance (miscellaneous) Population Antibodies Monoclonal Humanized Drug Costs chemistry.chemical_compound Quality of life (healthcare) Environmental health medicine Humans education Pharmacology Toxicology and Pharmaceutics (miscellaneous) Asthma education.field_of_study Medical Assistance business.industry Health Policy Public health medicine.disease Benralizumab Health assessment chemistry Quality of Life Interleukin-5 business Mepolizumab Brazil medicine.drug |
| Zdroj: | Value in Health Regional Issues. 26:169-181 |
| ISSN: | 2212-1099 |
| Popis: | Objectives To evaluate the efficacy and safety of anti-interleukin-5 class therapy agents in the treatment of eosinophilic asthma and the financial impact of these drugs on the Brazilian and Mato Grosso public health systems. Methods The literature review in important databases was guided by a structured research question including patient or population, intervention, comparator, outcome and type of study. The retrieved studies went through a screening, selection, data extraction, and methodological quality assessment process. A model with two scenarios, one with mepolizumab and the other with benralizumab, was created for budget impact analysis. Results Evidence indicated that anti-interleukins-5 have an acceptable safety profile and can reduce exacerbation rates by up to 50% in the population with eosinophilic asthma; however, they showed no significant difference in quality of life. The adoption of these drugs in the Brazilian health system can impact the budget from R$ 40,379,731.50 to R$ 140,301,211.34 depending on the drug incorporated, considering a time horizon of 5 years. From the perspective of the state of Mato Grosso, the budget impact may reach, in the fifth year, an amount of R$ 1,301,210.58 and R$ 2,050.687.62 for the scenarios with mepolizumab and benralizumab, respectively. Conclusion Anti-interleukins-5 are promising treatments for eosinophilic asthma because they minimise exacerbations and are well tolerated and safe. The financial impact is large, implying that technology costs may be a barrier to accessing this treatment class. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect